Enveric Biosciences Inc

NASDAQ:ENVBUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.

Contact Information

Headquarters

4851 Tamiami Trail N, Suite 200NAPLES, FL, United States 34103

Phone

239-302-1707

Fax

732-243-9254

Executives

Non-Executive Independent Chairman of the Board

Mike Webb

Chief Executive Officer, Director

Joseph Tucker

Chief Financial Officer

Kevin Coveney

Chief Innovation Officer

Peter Facchini

Independent Director

George Kegler